Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
+$0.05 today
- Market cap
- $630.03M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
Volume 2.90M
Average 1.76M
ABUS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Arbutus Biopharma CorporationNASDAQ: ABUS
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$177.58M, compared with $1.23M a year earlier. Trailing-twelve-month accounts receivables was -$177.45M.
Context
- Accounts receivables amounted to 9.8% of revenue in FY2025, down 0.5 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$177.58M or moves back toward the trailing-twelve-month quarterly average of -$44.36M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 1.38M USD
- Year-over-year change
- +317.2%
- 4-year CAGR
- +35.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.38M | +317.2% |
| FY2024 | 2024-12-31 | (633K) | -49.3% |
| FY2023 | 2023-12-31 | (424K) | +6.4% |
| FY2022 | 2022-12-31 | (453K) | -209.7% |
| FY2021 | 2021-12-31 | 413K | — |
Accounts Receivables vs competitors
How ABUS compares with its peers on the latest reported figures
- ABUS's LTM Mar 2026 accounts receivables of $177.45M is the 2nd largest of the 9 companies compared; the peer median is $225.5K.
- Its year-over-year change of -18642.7% is the lowest of 7, against a peer median of -22.9%.
- Accounts receivables amounts to 92.7% of revenue for ABUS, versus a peer median of 4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $357.64M | +48.4% | +99.1% | 7.4% | |
| LTM Mar 2026 | $177.45M | -18642.7% | — | 92.7% | |
| LTM Mar 2026 | $32.8M | +4000.1% | +39.1% | 47.4% | |
| LTM Mar 2026 | $8.33M | — | — | 904.4% | |
| LTM Sep 2026 | $3.29M | -94.2% | — | 0.7% | |
| LTM Mar 2026 | $451K | -1148.8% | +17.0% | 0.6% | |
| LTM Mar 2026 | $8.07K | -96.4% | +481.9% | — | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ABUS) | $225.5K | -22.9% | +69.1% | 4.1% | |
Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (76.25M) | (69.46M) | (72.85M) | (69.92M) | (33.5M) |
| Depreciation & Amortization | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| Deferred Income Tax | (8.18M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.42M | 7.18M | 9.3M | 8.99M | 6.95M |
| Change in Working Capital | 930K | 29.24M | (18.23M) | (2.83M) | (10.02M) |
| Accounts Receivables | 413K | (453K) | (424K) | (633K) | 1.38M |
| Inventory | (1.91M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.91M | 5.22M | 0 | 0 | (2.11M) |
| Other Working Capital | 517K | 24.48M | (17.81M) | (2.2M) | (9.29M) |
| Other Non-Cash Items | 7.79M | (3.75M) | (5.56M) | (2.47M) | (3.43M) |
| Operating Cash Flow | (67.53M) | (35.36M) | (85.94M) | (64.85M) | (39.64M) |
| Capital Expenditures | (809K) | (512K) | (1.01M) | (182K) | 0 |
| Acquisitions (Net) | 1.81M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (82.22M) | (130.43M) | (80.51M) | (141.51M) | 12.87M |
| Sales of Investments | 70.35M | 56M | 132.27M | 164.64M | 155.28M |
| Other Investing Activities | (1.81M) | 0 | 20K | 0 | (152.56M) |
| Investing Cash Flow | (12.68M) | (74.94M) | 50.77M | 22.95M | 15.58M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 134.67M | 20.32M | 29.85M | 44.12M | 5.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (12.14M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 14.71M | 11.49M | 795K | 7.87M | 0 |
| Financing Cash Flow | 137.24M | 31.81M | 30.65M | 52M | 5.72M |
| Effect of Forex Changes | 5K | (22K) | 25K | (49K) | 14K |
| Net Change in Cash | 57.03M | (78.51M) | (4.49M) | 10.05M | (18.32M) |
| Free Cash Flow | (68.34M) | (35.87M) | (86.94M) | (65.03M) | (39.64M) |
Arbutus Biopharma Corporation
NASDAQ:ABUS
Intrinsic Alpha fair value
Locked
Current Price
$4.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.